Posted by Michael Wonder on 24 Feb 2022
Once a day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS
24 February 2022 - The 20th cancer treatment to go through the Cancer Drugs Fund following a period of managed access has been recommended for routine use in the NHS by NICE in final draft guidance published today.
Taken as a once a day capsule, niraparib (Zejula, GSK) is recommended for people whose cancer has relapsed and have a specific mutation in their cancer known as a BRCA mutation and who have had two courses of platinum-based chemotherapy.
